• Home
  •  / PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals

OverviewSuggest Edit

PhaseBio Pharmaceuticals is a biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The Company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance.

TypePublic
Founded2002
HQMalvern, USMap
Websitephasebio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)22
Revenue (FY, 2018)$668 K
Share Price (Nov 2019)$3.5 (+6%)

Key People/Management at PhaseBio Pharmaceuticals

Jonathan Mow

Jonathan Mow

CEO
Susan Arnold

Susan Arnold

Vice President of Preclinical and CMC
Jim Ballance

Jim Ballance

Vice President of Research and Scientific Affairs
Glen Burkhardt

Glen Burkhardt

Vice President of Human Resources
John Lee

John Lee

Chief Medical Officer
John Sharp

John Sharp

CFO
Show more

PhaseBio Pharmaceuticals Office Locations

PhaseBio Pharmaceuticals has an office in Malvern
Malvern, US (HQ)
1 Great Valley Pkwy #30
Show all (1)

PhaseBio Pharmaceuticals Financials and Metrics

PhaseBio Pharmaceuticals Revenue

PhaseBio Pharmaceuticals's revenue was reported to be $668 k in FY, 2018
USD

Revenue (Q3, 2019)

241.0k

Net income (Q3, 2019)

(11.4m)

EBIT (Q3, 2019)

(11.6m)

Market capitalization (15-Nov-2019)

101.6m

Closing stock price (15-Nov-2019)

3.5

Cash (30-Sep-2019)

81.8m

EV

29.6m
PhaseBio Pharmaceuticals's current market capitalization is $101.6 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

668.0k

General and administrative expense

2.1m2.3m4.9m

R&D expense

7.4m6.2m15.5m

Operating expense total

9.5m8.5m20.3m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

411.0k653.0k703.0k241.0k

General and administrative expense

565.0k1.1m2.3m2.4m2.8m

R&D expense

1.3m4.4m5.7m7.8m9.0m

Operating expense total

1.9m5.4m8.0m10.2m11.8m
show all
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

3.7m13.4m61.0m

Accounts Receivable

233.0k

Prepaid Expenses

169.0k340.0k1.3m

Current Assets

3.9m13.7m62.6m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

8.7m24.3m51.9m90.3m81.8m

Accounts Receivable

670.0k1.2m

Prepaid Expenses

218.0k216.0k1.5m3.4m

Current Assets

9.0m25.0m54.1m94.9m83.4m
show all
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(9.2m)(10.2m)(23.8m)

Depreciation and Amortization

92.0k96.0k105.0k

Accounts Payable

(344.0k)(213.0k)1.3m

Cash From Operating Activities

(9.7m)(8.3m)(17.1m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019

Net Income

(7.7m)(19.0m)(7.3m)(16.5m)

Depreciation and Amortization

68.0k82.0k31.0k74.0k

Accounts Payable

(39.0k)558.0k225.0k1.2m

Cash From Operating Activities

(5.8m)(10.2m)(8.7m)(18.9m)
show all
USDY, 2019

EV/EBIT

-2.5 x

EV/CFO

-1.6 x

Financial Leverage

1.2 x
Show all financial metrics

PhaseBio Pharmaceuticals Online and Social Media Presence

PhaseBio Pharmaceuticals's Trends

Embed Graph

PhaseBio Pharmaceuticals News and Updates

March 19, 2019

Thinking about buying stock in Altimmune Inc., Dare Bioscience Inc., Phasebio Pharmaceuticals Inc., Stoneco Ltd., or Tilray Inc.?

NEW YORK, March 19, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, DARE, PHAS, STNE, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

 PhaseBio Pharmaceuticals Frequently Asked Questions

  • When was PhaseBio Pharmaceuticals founded?

    PhaseBio Pharmaceuticals was founded in 2002.

  • Who are PhaseBio Pharmaceuticals key executives?

    PhaseBio Pharmaceuticals's key executives are Jonathan Mow, Susan Arnold and Jim Ballance.

  • How many employees does PhaseBio Pharmaceuticals have?

    PhaseBio Pharmaceuticals has 22 employees.

  • What is PhaseBio Pharmaceuticals revenue?

    Latest PhaseBio Pharmaceuticals annual revenue is $668 k.

  • What is PhaseBio Pharmaceuticals revenue per employee?

    Latest PhaseBio Pharmaceuticals revenue per employee is $30.4 k.

  • Who are PhaseBio Pharmaceuticals competitors?

    Competitors of PhaseBio Pharmaceuticals include Sangamo BioSciences, PanOptica and Amicus Therapeutics.

  • Where is PhaseBio Pharmaceuticals headquarters?

    PhaseBio Pharmaceuticals headquarters is located at 1 Great Valley Pkwy #30, Malvern.

  • Where are PhaseBio Pharmaceuticals offices?

    PhaseBio Pharmaceuticals has an office in Malvern.

  • How many offices does PhaseBio Pharmaceuticals have?

    PhaseBio Pharmaceuticals has 1 office.